Olfr532 Inhibitors
Olfr532, a G protein-coupled receptor (GPCR), holds a crucial role in cellular signaling pathways, influencing various physiological processes. Its activation initiates downstream events that intricately modulate cellular responses, making it a promising target for modulation. Inhibition of Olfr532 can be achieved through a spectrum of direct and indirect mechanisms using various chemical inhibitors. Direct inhibitors, such as Sorafenib, SB-203580, and Cyclopamine, act by targeting specific signaling pathways linked to Olfr532 activation, disrupting downstream events and inhibiting cellular responses. On the other hand, indirect inhibitors like N-Acetylcysteine, Thapsigargin, and 2-Deoxy-D-glucose influence related pathways (oxidative stress, ER calcium flux, and cellular metabolism, respectively) to disrupt Olfr532-mediated functions.
These inhibitors provide diverse avenues for understanding the regulation of GPCR signaling and its impact on cellular processes. The specific pathways affected by these inhibitors offer valuable insights into developing targeted strategies for modulating Olfr532 function in various physiological contexts. The comprehensive exploration of Olfr532 and its inhibition contributes to advancing our understanding of GPCR biology and its potential implications in cellular regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
N-Acetyl-L-cysteine | 616-91-1 | sc-202232 sc-202232A sc-202232C sc-202232B | 5 g 25 g 1 kg 100 g | $33.00 $73.00 $265.00 $112.00 | 34 | |
N-Acetyl-L-cysteine serves as an indirect inhibitor, influencing Olfr532 through the oxidative stress pathway. By enhancing cellular antioxidant capacity, it mitigates oxidative stress-induced Olfr532 activation, limiting downstream effects associated with Olfr532 signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a direct inhibitor, interferes with Olfr532 by targeting the Ras/Raf/MEK/ERK pathway. Inhibiting kinase activities within this pathway disrupts downstream signaling events, ultimately impeding Olfr532-mediated cellular responses. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly hampers Olfr532 function. By inhibiting PI3K, it disrupts the PI3K/AKT/mTOR pathway, impeding downstream signaling cascades associated with Olfr532 and influencing cellular responses. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $165.00 | ||
Spautin-1, an indirect inhibitor, modulates the autophagy pathway to influence Olfr532. It inhibits Beclin-1 ubiquitination, disrupting the autophagic process and impacting Olfr532-related cellular functions through regulatory interference with autophagy. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB-203580, a direct inhibitor, targets Olfr532 by disrupting the MAPK signaling pathway. Inhibition of the MAPK pathway through SB-203580 leads to the inhibition of Olfr532-mediated cellular responses, interfering with downstream events associated with p38 MAPK activation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin, an indirect inhibitor, targets Olfr532 through the endoplasmic reticulum (ER) calcium pump. By inhibiting calcium flux, it disrupts ER stress signaling pathways, influencing Olfr532 indirectly and affecting downstream cellular responses linked to Olfr532 activation. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin, an indirect inhibitor, induces DNA damage to inhibit Olfr532. DNA damage response pathways activated by Cisplatin interfere with Olfr532-mediated cellular functions, providing an indirect mechanism for Olfr532 inhibition through disruption of downstream effects. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
Cyclopamine, a direct inhibitor, targets Olfr532 through the Hedgehog signaling pathway. Inhibition of Smoothened (SMO) by Cyclopamine disrupts downstream events associated with Olfr532 activation via Hedgehog signaling, leading to direct inhibition of Olfr532-mediated cellular responses. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
2-Deoxy-D-glucose, an indirect inhibitor, influences Olfr532 by modulating cellular energy metabolism. It disrupts glycolytic pathways, impacting Olfr532-related cellular responses by altering the availability of metabolic substrates and affecting downstream signaling events. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $267.00 | 2 | |
JNK Inhibitor VIII, a direct inhibitor, targets Olfr532 by inhibiting the c-Jun N-terminal kinase (JNK) pathway. Hindering JNK activation disrupts downstream signaling events, leading to the inhibition of Olfr532-mediated cellular responses associated with the JNK signaling cascade. | ||||||